Serum vitamin D metabolites and PTH were measured in seven subjects with a history of previous partial gastrectomy (PGX) and metabolic bone disease. 1-3) . Some patients have an associated postgastrectomy malabsorption syndrome with steatorrhea, but in others, intestinal absorption seems normal. We previously have documented normal intestinal absorption of vitamin D in five subjects with PGX (4), and vitamin D deficiency is reversed by physiological doses of vitamin D. It is therefore unclear why subjects with PGX should suffer from vitamin D deficiency, especially when the diet in the United Kingdom is not the major source of vitamin D. In the United Kingdom, the main source of vitamin D for an individual is cutaneous synthesis, and the principal cause of vitamin D deficiency is sunlight deprivation. A diet lacking in calcium produces secondary hyperparathyroidism (2°HPT) and elevated serum 1,25-dihydroxyvitamin D (1, 25-(OH) 2 D) (the active metabolite of vitamin D); in the rat this is associated with enhanced metabolic clearance of the precursor 25-hydroxyvitamin D (25OHD) (5). We have shown a similar mechanism in humans, and in a variety of clinical situations, the elimination t 1 ⁄2 of a tracer dose of tritiumlabeled 25OHD ([ 3 H]25OHD 3 ) is inversely related to the prevailing serum concentration of 1,25-(OH) 2 D (6, 7). Furthermore, an artificially induced abrupt increase in serum 1,25-(OH) 2 D is followed quickly by a reduction of t 1 ⁄2 [ 3 H]25OHD 3 (7). Increased serum 1,25-(OH) 2 D and low serum 25OHD have been reported in subjects after gastrectomy (8, 9), suggesting that problems with calcium absorption may lead to 2°HPT in a way similar to the situation induced experimentally in the rat by Clements et al. (5).
V ITAMIN D deficiency, osteomalacia, and osteoporosis are recognized complications in patients who have had previous partial gastrectomy (PGX) (1) (2) (3) . Some patients have an associated postgastrectomy malabsorption syndrome with steatorrhea, but in others, intestinal absorption seems normal. We previously have documented normal intestinal absorption of vitamin D in five subjects with PGX (4), and vitamin D deficiency is reversed by physiological doses of vitamin D. It is therefore unclear why subjects with PGX should suffer from vitamin D deficiency, especially when the diet in the United Kingdom is not the major source of vitamin D. In the United Kingdom, the main source of vitamin D for an individual is cutaneous synthesis, and the principal cause of vitamin D deficiency is sunlight deprivation. A diet lacking in calcium produces secondary hyperparathyroidism (2°HPT) and elevated serum 1,25-dihydroxyvitamin D (1, 25-(OH) 2 D) (the active metabolite of vitamin D); in the rat this is associated with enhanced metabolic clearance of the precursor 25-hydroxyvitamin D (25OHD) (5) . We have shown a similar mechanism in humans, and in a variety of clinical situations, the elimination t 1 ⁄2 of a tracer dose of tritiumlabeled 25OHD ([ 3 H]25OHD 3 ) is inversely related to the prevailing serum concentration of 1,25-(OH) 2 D (6, 7). Furthermore, an artificially induced abrupt increase in serum 1,25-(OH) 2 D is followed quickly by a reduction of t 1 ⁄2 [
3 H]25OHD 3 (7) . Increased serum 1,25-(OH) 2 D and low serum 25OHD have been reported in subjects after gastrectomy (8, 9) , suggesting that problems with calcium absorption may lead to 2°HPT in a way similar to the situation induced experimentally in the rat by Clements et al. (5) .
We have studied a group of subjects with a history of PGX to examine the effect on the t 1 ⁄2 [ 3 H]25OHD 3 . In a subset with 2°HPT, we have repeated the investigation after suppression of the 2°HPT with large oral doses of calcium (1-2 g/day).
Subjects and Methods

Subjects and protocol
Seven patients were studied (five female, two male) aged 53-73 yr. Clinical details are given in Table 1 . The protocol was approved by the local ethical committee, and each patient gave informed consent. After an overnight fast, a rapid iv injection of 5 Ci (185 KBq) [26,27-3 H]25OHD 3 (762 GBq/mmol) Amersham International plc (Amersham Bucks, UK) in 5 mL of the patients' own fasting plasma was given into one arm at 0900 h. Blood samples were taken immediately and at regular intervals for 14 days. The decline of [ 3 H]25OHD 3 in the patients' plasma was followed by direct liquid scintillation counting of 400-L samples with 4-mL Optiphase Safe Wallac (LKB) in an LKB 1217 Rackbeta scintillation spectrometer (LKB, South Croydon, UK). The decline of 3 H in the plasma after an iv injection of [ 3 H]25OHD 3 is described by a biphasic exponential curve (10 A [log plasma] concentration/time curve for the decay of plasma 3 H was constructed for each subject, and the gradient of the slope from the fourth day after injection was determined by least-squares regression analysis. The long-phase t 1 ⁄2 for [ 3 H]25OHD 3 in plasma was calculated using the formula: t 1 ⁄2 ϭ log2/gradient (7).
Assays
Serum vitamin D metabolites were extracted for assay as previously described (11) . Metabolites were separated by automated high-performance liquid chromatography (Waters Associates). 25OHD was quantified by competitive protein-binding assay (12) using normal human serum as the source of vitamin D-binding protein at a dilution of 1:20,000. The reference range was 10.8 -58.5 nmol/L (inter-and intraassay coefficients of variation 8.8% and 7.8%, respectively). 1,25-(OH) 2 D was measured by RIA using monoclonal antibody 5F2 (13) with a reference range of 48 -120 pmol/L (inter-and intraassay coefficients of variation 10.7% and 7.8%, respectively).
Serum PTH was measured by immunoradiometric assay using a Nichols Institute Allegro Kit for intact PTH (Saffron Walden, UK, reference range 10 -60 ng/L). Serum calcium, phosphate, albumin, creatinine, and alkaline phosphatase were analyzed on a multichannel autoanalyzer (American Monitor Corporation, Indianapolis, IN). Serum calcium was corrected for changes in serum albumin concentration according to the formula: corrected Ca ϭ actual Ca ϩ (40 Ϫ serum albumin) ϫ 0.02 mmol/L (14) .
Statistics
Statistical analysis was undertaken using Minitab (Minitab Inc., State College, PA). The distributions of all variables, apart from alkaline phosphatase and 25OHD, did not deviate from normality. Association between the variables was sought using Spearman's rank correlation coefficient (r s ) followed by stepwise linear regression to control for multiple interactions. The differences between group means were examined using Student's two-tailed paired t tests; values are expressed as mean Ϯ sd.
Results
Plasma biochemistry and values for the calculated t 1 ⁄2 25OHD 3 are detailed in Table 2 . All patients except patient 4 had normal serum calcium, phosphate, and alkaline phosphatase and no biochemical evidence of osteomalacia. Patient 4 had an antecedent history of osteomalacia, and his biochemistry was consistent with the healing phase of that disease. All subjects were initially vitamin D-replete with serum 25OHD above 25 nmol/L, median 37.5 (27.5-101.3) nmol/L. Mean serum 1,25-(OH) 2 D was raised in the group, 175 Ϯ 72 pmol/L, with elevated levels in five of the seven subjects. Mean serum PTH also was raised at 66.6 Ϯ 27.2 ng/L with high levels in four patients, who also had raised 1,25-(OH) 2 D concentrations.
Patients 2, 4, 6, and 7 (Table 2) , who had high PTH and raised 1,25-(OH) 2 D levels, were restudied after attempts to suppress 2°HPT with oral calcium supplements; none became hypercalcemic with this treatment. In three of these patients, serum PTH fell to within the reference range; PTH remained elevated in patient 4, and the change in the group (from 82 Ϯ 24 to 52 Ϯ 24 ng/L) was not significant, P ϭ 0.104. 1,25-(OH) 2 D levels became normal, the mean falling from 210 Ϯ 61 to 116 Ϯ 28 pmol/L, P ϭ 0.015. Initial t 1 ⁄2 25OHD 3 ranged from 21.2-10.9 days (Table 2) . After calcium supplementation, which lowered serum 1,25-(OH) 2 D, mean t 1 ⁄2 25OHD 3 increased by 35%, from 13.2 Ϯ 1.9 to 18.9 Ϯ 3.1 days, P ϭ 0.016. A highly significant inverse relationship was demonstrated ( (Fig. 2, r s ϭ Ϫ0.64, P ϭ 0.0001). These aggregated results include data from patients with primary hyperparathyroidism (1°HPT) before and after surgery (6) , and patients with disorders of bone and mineral metabolism before and after treatment with calcium or 1,25-(OH) 2 D (7).
Discussion
The present study in PGX patients reaffirms the relationship between the prevailing serum concentration of 1,25-(OH) 2 D and the t 1 ⁄2 for 25OHD 3 in plasma. We have shown previously that the variation in observed t 1 ⁄2 25OHD 3 without change in vitamin D or parathyroid status is less than 2% when two consecutive measurements are made in individuals without change in vitamin D or parathyroid status (7) . The present changes in t 1 ⁄2 varied from 23-52% in the four patients in whom calcium supplements were given to suppress the high serum 1,25-(OH) 2 D values and are therefore significant and not explicable in terms of methodological error. In a previous study (7) of patients undergoing parathyroidectomy for 1°HPT, a reduced t 1 ⁄2 25OHD 3 was accompanied by increased fecal excretion of tritium as a result of enhanced metabolic inactivation of 25OHD 3 . Meyer et al. (15) have documented increased fecal loss of cholecalciferol after iv administration of radioactive cholecalciferol to gastrectomized rats; however, no data were available regarding serum 1,25-(OH) 2 D levels. Nilas et al. (8) found raised 1,25-(OH) 2 D levels in a group of patients with PGX in whom calcium absorption was low-normal, and PTH (using a C terminal assay) was not raised. Rao et al. (16) found evidence of 2°HPT in a subset of women with a past history of PGX. These collected observations suggest that after PGX, the intestinal absorption of calcium may be impaired and is only compensated for by the induction of 2°HPT and consequent increase in serum 1,25-(OH) 2 D.
The mechanisms whereby 1,25-(OH) 2 D enhances the catabolism of 25OHD are not fully understood but may involve reactions in both liver and kidney. 1,25-(OH) 2 D is known to suppress renal 1␣-hydroxylase activity, thus down-regulating its own synthesis, and to stimulate 24-hydroxylase activity. Halloran et al. (17) have shown that 1,25-(OH) 2 D infusions increase the clearance of 24,25-(OH) 2 D and, in a study of men with Billroth II gastrectomy (18), 24,25-(OH) 2 D concentrations were lowered whereas 1,25-(OH) 2 D levels were increased, supporting Halloran's data (18) .
There is no evidence for hepatic 24-hydroxylation of 25OHD 3 , and in experiments investigating the effects of rearing rats on a low calcium diet to induce 2°HPT or sc infusing 1,25-(OH) 2 (23, 24) and thus can be regarded as a target organ for 1,25-(OH) 2 D 3 activity.
In the present study, PTH seems to have an effect upon t 1 ⁄2 25OHD 3 that was independent of the effect of 1,25-(OH) 2 D. We have not observed this effect previously and have found the relationship between t 1 ⁄2 25OHD 3 and 1,25-(OH) 2 D in the absence of PTH (7) . The mechanism(s) whereby PTH itself may be influencing the t 1 ⁄2 25OHD 3 , other than via enhanced synthesis of 1,25-(OH) 2 D, is not clear, and our present observations may be similar to the experimental data obtained by Bolt et al. (19) and described above. Regardless of the mechanism responsible for the phenomenon we have observed, it is clear that the increased clearance of 25OHD in the presence of high 1,25-(OH) 2 D in subjects with PGX helps to explain the development of vitamin D deficiency when the supply of vitamin D is limited. Ultimately, when the amount of 25OHD substrate decreases to a critical point, synthesis of 1,25-(OH) 2 D will fall and calcium absorption will decrease. If the supply of vitamin D is adequate, the long-term effects of raised 1,25-(OH) 2 D and PTH (2°HPT) may be to enhance bone turnover, exacerbate any preexisting remodeling imbalance, and lead to osteopenia or osteoporosis, all wellknown complications of PGX (18) .
